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Caffeine Versus Methylphenidate and d-Amphetamine in Minimal Brain 
Dysfunction: A Double-Blind Comparison 
By LCDR Robert D. Huestis, MC, USN, L. Eugene Arnold, M.ED., M.D., and 
Donald J. Smeltzer, M.A. 
The authors compared the efficacy of caffeine, methylphenidate, and d-amphetamine in children with 
minimal brain dysfunction using a double-blind crossover design. The slight improvement with caffeine 
was not significantly better than placebo. Both prescription drugs resulted in significant improvement and 
were significantly superior to caffeine. The authors suggest that the discrepancy between these results and 
an earlier, more optimistic report may stem from the use in this study of pure caffeine rather than whole 
coffee. 
In recent years a growing public and professional concern about the use of Schedule II 
stimulants to treat hyperkinetic children has sparked a desire to find a "safer" medication that has 
equal efficacy. Caffeine has been one of the drugs proposed as an alternative. Schnackenberg's 
initial report of a pilot study was promising (1); however, he cautioned that controlled studies were 
necessary. We thought it would be particularly useful to compare caffeine with the two most 
widely accepted and prescribed agents, d-amphetamine and methylphenidate. Although our study 
is not complete, the results seem so clinically relevant that we are reporting a preliminary 
analysis of the first half of the sample. 
Method and Design 
After an initial two-week placebo washout, caffeine, d-amphetamine, and methylphenidate 
were compared in a double-blind randomized Latin square crossover design. The subjects were 18 
children consecutively admitted to the Ohio State University Child Psychiatry Clinic (12 boys 
and 6 girls, mean age = 8.5 years) who met the following criteria: 
1. Diagnosable minimal brain dysfunction with such symptoms as hyperactivity, distractibility, 
short attention span, incorrigibility, labile explosiveness, uncoordination, and perceptuomotor 
problems. 
2. A total score of 24 or more on the first six items of Davids' Hyperkinetic Rating Scale (2). 
3. Age between 5 and 12 years. 
4. Enrollment in some sort of school setting in order to obtain teachers' ratings. 
5. No psychoactive medications in the preceding month. 
6. Failure to respond to a two-week placebo washout period. 
In the initial two-week period, 10 children received "true" placebo and 8 received a 
combination of vitamins. Because comparison of these two groups revealed no significant 
differences between the true placebo and the vitamin group, results for these patients were pooled 
and reported as placebo scores for the whole sample. Only 2 subjects, both of whom had received 
the true placebo, were placebo responders. 
All medications were dispensed by a pharmacist who randomized the order of drug 
assignment. The matched dosage forms were white opaque capsules in the following strengths: 80 
mg of caffeine, 5 mg of d-amphetamine, and 10 mg of methylphenidate. These dosage ratios were 
selected to reflect approximate relative potencies suggested by the literature. Dosage size was 
selected so that one to six capsules would include the recommended daily dosage. Specifically, 
Schnackenberg (1) recommended 200 to 300 mg of caffeine per day and stated that increasing 
the dosage above 300 mg did not elicit any further improvement. 
Each of the drug conditions lasted three weeks, with a minimum of three telephone 
consultations for adjustment of dosage (the average number of contacts was six). The ascending 
dosage schedule for each medication was as follows: day 1—one capsule in the morning, day 
2— one in the morning and one at noon, and day 3—two in the morning and one at noon. All 
parents were instructed to contact the clinic on the fourth day, at which time further adjustments 
were made depending on information they provided. 
At each of the visits, including the predrug assessment, the following information was 
collected: 1) a parents' symptom checklist reported by Arnold and Smeltzer (3), 2) Conners' 
Teachers' Behavior Checklist (4), 3) Davids' Hyperkinetic Rating Scale completed by the parents 
(2), 4) Davids' Hyperkinetic Rating Scale completed by the teacher, and 5) a target symptom 
assessment in the manner described by Arnold and associates (5). 
Results 
Since the amount of medication for each subject was individualized during the three-week 
interval, it is important to note that all the subjects received at least 300 mg of caffeine per day for 
at least one week. The optimal effective dosage range for d-amphetamine was 5 to 25 mg (average 
= 20 mg) and for methylphenidate, 30 to 60 mg (average = 40 mg). 
Table 1 shows the mean target symptom ratings by two psychiatrists for each of the five 
visits, the average rating for Davids' Hyperkinetic Rating Scale, as reported by both parents and 
teachers, the average ratings from the symptom checklist by parents, and the average ratings of the 
behavior checklist by teachers. 
Paired t tests of all these data clearly indicate that caffeine was not significantly more 
effective than placebo, but both d-amphetamine and methylphenidate were (p<.01). More 
importantly, comparison of caffeine to methylphenidate and d-amphetamine shows caffeine to be 
significantly less effective. The one exception to this pattern was the nonsignificance of the 
methylphenidate versus caffeine comparison on the teachers' hyperkinetic rating scale. In all other 
instances, both d-amphetamine and methylphenidate were significantly superior to both caffeine 
and placebo. The two effective drugs were not significantly different from each other, nor was 
placebo different from the predrug condition. 
Upon completion of the study, 16 subjects were found to have improved sufficiently to 
warrant continuation of one of the three medications. Nine took d-amphetamine, 6 took 
methylphenidate, and 1 took caffeine. (One month after completion of the study, the child on 
caffeine had to be switched to d-amphetamine because his previous symptoms returned.) 
Discussion 
Preliminary results of this study seem to indicate that caffeine does not offer hyperkinetic 
children the same therapeutic benefits as d-amphetamine and methylphenidate. It should be added 
that the clear differences illustrated in table 1 were entirely consistent with the clinical judgment of 
the experimentally blind clinician-investigator. Difficulties repeatedly arose during the study after a 
child who had received either d-amphetamine or methylphenidate was switched to caffeine. 
Usually, this involved a parents' request to terminate that three-week trial. The caffeine treatment 
also prompted four spontaneous notes from teachers inquiring as to what had caused such rapid 
deterioration following obvious gains in previous trial weeks. 
Perhaps a word should be said about the rather high percentage of children who were found 
to be drug responders (89 percent). This is probably a reflection of the fact that the study included 
two medications known to be helpful in this disorder. This finding would seem to emphasize the 
clinical value of trying more than one stimulant, not only when the child fails to respond to the first 
medication tried but also when there is benefit, but not to the degree expected, or there are 
annoying side effects. Both efficacy and side effects were considered in the decision as to which 
medication (if any) a child would receive at the completion of the study. Since the subjects had 
tried both d-amphetamine and methylphenidate, we were able to feel confident that the medication 
had been "matched" to the individual child. 
The small sample size does not warrant comment regarding the nonsignificant difference 
between d-amphetamine and methylphenidate. This issue may be clarified by our present efforts to 
expand the sample to its originally projected size. 
Another reason for sample expansion is that the nonsignificant trend for caffeine to be 
slightly more effective than placebo in this analysis may reach significance in a larger sample. 
Caffeine may have a real efficacy that was not apparent in this study because of small sample size. 
This could carry practical clinical implications in the risk-benefit decision. Of course, caffeine's 
significant inferiority to the two prescription stimulants is not likely to disappear with sample 
expansion. However, if caffeine is considered much safer and does prove to have some slight 
efficacy, it might make sense in many cases to try it before proceeding to "dangerous" drugs. 
Predrug     
Measure  Placebo Methylphenidate d-Amphetamine Caffein
e
Target symptom rating, psychiatrists 
(l=best, 9=worst)* 
     
5.00 5.33 3.42 3.22 4.97 
Hyperkinetic Rating Scale, parents 
(1 = least and 6=most 
hyperkinetic)** 
     
5.14 4.97 4.21 4.13 4.89 
Hyperkinetic Rating Scale, 
teachers*** 
4.92 4.90 4 .11  3.88 4.67 
Symptom checklist, parents (1 =no      
 2.37 2.31 1.86 1.82 2.14 
Behavior checklist, teachers (1 =no   
 2.34 2.36 1.91 1.86 2.32 
*Significant differences (paired t tests for all comparisons): placebo versus both methylphenidate and d-amphetamine 
(p<.00l) and caffeine versus both methylphenidate and d-amphetamine (p<.01).  
**Significant differences (p<.01): placebo versus both methylphenidate and d-amphetamine and caffeine versus both 
methylphenidate and d-amphetamine.  
***Placebo versus both methylphenidate and d-amphetamine (p<.00l) and d-amphetamine versus caffeine 
(p<.001). 
†Placebo versus both methylphenidate (p< .01) and d-amphetamine (p< .001) and caffeine versus both 
methylphenidate and d-amphetamine (p< .05). 
††Placebo versus both methylphenidate (p<.01) and d-amphetamine (p<.001) and caffeine versus both methylphenidate 
(p<. 02) and d-amphetamine (p<. 001). 
Table 1 Comparison of the Efficacy of Methylphenidate, d-Amphetamine, and Caffeine in 18 Children 
with Minimal Brain Dysfunction 
One possible explanation for the discrepancy between our findings and those of 
Schnackenberg's pilot study (1) is that he used whole coffee, while we used pure caffeine. Could it 
have been something in the coffee besides the caffeine that effected the improvement he observed? 
This question deserves study, which could easily be done using whole freeze-dried coffee in the 
matched capsules. If this proved effective, a further possible refinement would be to try 
decaffeinated coffee to see if the other coffee constituent required the presence of caffeine to be 
effective. 
At the present time, however, it does not appear that caffeine alone will be a very effective 
addition to the treatment armamentarium for minimal brain dysfunction. 
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